VaxSyna develops low-cost vaccines and therapeutics against global health challenges with a focus on reaching under-served populations.
Preclinical data on vaccines created using our technology platforms, including our lead HPV vaccine, have been published in several peer-reviewed journals. We have received an STTR grant to complete late pre-clinical experiments on the temperature stability and optimal delivery route of our vaccine and plan to write a phase II SBIR grant that will carry us through non-human primate studies. We have exclusive license agreements for the all relevant patents.
Problem or Opportunity
Our team is passionate about addressing global health challenges through innovative vaccine platforms that can be cheaply manufactured and equitably distributed. Our first product addresses the urgent global need for an HPV vaccine that provides greater cross-strain protection at a lower price than current market options and targets the low-to-middle income countries that bear a disproportionate burden of HPV-related cancers.
Solution (product or service)
VaxSyna is proposing to create a cheaper, more broadly protective, two-dose HPV vaccine candidate to reduce the incidence of HPV-related cancers in LMIC. Our solution uses our patented platform vaccine technology that co-delivers two vaccine platforms. Our vaccine solution uses the highly conserved L2 HPV protein, a vaccine target that has been shown to provide protection against up to 22 HPV strains. The breadth of this protection includes strains that are prevalent in LMIC and is unmatched by current HPV vaccines, which protect at most against 9 strains.
Our strategy for acquiring customers is as follows: we seek to obtain WHO prequalification and compete for public purchasing directly from our vaccine manufacturer by vaccine procurement agencies including the UN UNICEF supply division, Pan American Health Organization (PAHO), and the GAVI alliance. We will also work with private purchasers from National Technical Advisory Groups, such as the United States Advisory Committee on Immunization Practices. Our goal is to bring vaccines, developed with our platform system, through phase I/II clinical trials, then sub-license them to pharma companies
Incubation/Acceleration programs accomplishment
We are a part of the Center for Entrepreneurial Innovation incubator (https://www.ceigateway.com/).